AAM submitted comments to CMS, highlighting the extent and ways in which Part D sponsors and their PBMs engage in practices that favor, intentionally or unintentionally, more expensive reference drugs and biological products over generics.
AAM said that by including drugs with generics and biosimilars in development in the 15 drugs selected for negotiation, CMS highlights a central flaw in the IRA price setting scheme.